학술논문
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial
Document Type
Article
Author
Source
In: Arthritis Research and Therapy . (Arthritis Research and Therapy, 17 January 2012, 14(1))
Subject
Language
English
ISSN
14786354
14786362
14786362